Products

What will AGI do for Atevirdine?

This classification denotes a reverse transcriptase inhibitor with the molecular formula C21H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, N24015WC6D chemically known as piperazine, 1-(3-(ethylamino)-2-pyridinyl)-4-((5-methoxy-1h-indol-2-yl)carbonyl)-, monomethanesulfonate but generally known as atevirdine, which bears US NIH Compound Identifier 60848. European Medicines Agency schedules Atevirdine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05591MIG. The term ATEVIRDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34. ). Most nations schedule atevirdine under HS 29335995 and SITC 51576. As of Q4 2014, ATEVIRDINE remains the US FDA Preferred Term for this commodity. Atevirdine bears US NLM identifiers UMLS ID C0210243 and NCI Concept Code C73840. SMILES: CCNC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)OC.

How AGI delivers it

Four ways AGI delivers for Atevirdine

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Atevirdine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Atevirdine, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Atevirdine connects

measured by

  • Assay Puritymodel
  • Impurity Contentmodel
  • Particle Size Distributionmodel